What raloxifene is
Raloxifene is a selective estrogen receptor modulator, or SERM: it behaves like estrogen in some tissues and blocks it in others. On bone it acts like estrogen and slows bone loss. On breast tissue it blocks estrogen, which is why it has a second, separate role.
It is a 60 mg tablet taken once daily, with or without food.
What it does for bone — and what it does not
Raloxifene reduces the risk of vertebral fractures in postmenopausal women with osteoporosis. It has not been shown to reduce hip or other non-vertebral fractures. That distinction matters a great deal in practice: hip fracture is the outcome with the heaviest consequences, and a woman whose main risk is hip fracture is usually better served by a different drug.
It also does not build bone the way an anabolic agent does. It slows loss.
The breast cancer effect
Raloxifene reduces the risk of invasive breast cancer in postmenopausal women at increased risk. For a woman who has both low bone density and elevated breast cancer risk, this dual action is the main reason it gets chosen over a bisphosphonate.
It is a risk-reduction effect in women at increased risk, not a treatment for breast cancer and not a guarantee.
The risks that decide the conversation
- Blood clots. Raloxifene increases the risk of venous thromboembolism. It carries a boxed warning covering this, and also death from stroke in women with coronary heart disease or at increased risk of major coronary events. A personal history of clots generally rules it out.
- Hot flashes. It commonly triggers or worsens them, which makes it a poor fit for a woman still in the thick of vasomotor symptoms.
- Leg cramps are common.
- Prolonged immobility — surgery, a long flight, bed rest — requires a plan, because clot risk concentrates there.
One thing it cannot be used for
Raloxifene has specifically been studied as a way to hold bone after stopping denosumab, and it does not work for that: it did not control the high bone turnover or the spontaneous vertebral fracture risk that follows denosumab withdrawal. If you are coming off denosumab, raloxifene is not the bridge.
Who it tends to suit
A postmenopausal woman whose fracture risk is mainly spinal rather than hip, who has elevated breast cancer risk, who is past the worst of her hot flashes, and who has no clot history. Outside that profile, another option is usually more appropriate.
How it compares with the alternatives
| Raloxifene | Bisphosphonate | Estrogen therapy | |
|---|---|---|---|
| Vertebral fracture | Reduced | Reduced | Reduced |
| Hip fracture | Not shown | Reduced | Reduced |
| Hot flashes | Worsens | No effect | Improves |
| Breast cancer risk | Reduced in women at increased risk | No effect | Depends on regimen |
| Clot risk | Increased | No increase | Increased with oral; not shown with transdermal |
Read across the hip fracture row first. It is the single line that most often decides against raloxifene.
Practical points during treatment
- Plan around immobility. Stop before prolonged bed rest or major surgery as directed, and move around during long flights. Clot risk concentrates in exactly those windows.
- Leg cramps are common and are not a sign of anything dangerous, though they are a common reason women stop.
- Calcium and vitamin D still matter. Raloxifene does not replace them.
- It does not treat vaginal dryness. Because it blocks estrogen in some tissues, genitourinary symptoms usually need separate local treatment.
What to report promptly
- Swelling, pain or warmth in one leg, or sudden breathlessness or chest pain — possible clot
- New vision changes
- Any new fracture
How long women stay on it
There is no fixed course. It is continued while the balance of spinal fracture risk, breast cancer risk reduction and clot risk still favours it — a balance that shifts with age, since clot and stroke risk rise over time while the fracture picture may also change. That makes it a treatment worth actively reviewing every year or two rather than repeating on autopilot.